- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Arctic Bioscience AS: Arctic Bioscience - Minutes of the Extraordinary General Meeting | 3 | Oslo Børs | ||
| 05.11. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Notice of Extraordinary General Meeting on 19 November 2024 | 1 | Cision News | ||
| 29.10. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Q3 2024 Operational update | 3 | Cision News | ||
| 16.10. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Presentation for today's webcast | 4 | Cision News | ||
| 15.10. | Arctic Bioscience AS: Arctic Bioscience - Mandatory notification of trade | 1 | Oslo Børs | ||
| ARCTIC BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 15.10. | Arctic Bioscience AS: Arctic Bioscience - Invitation to webcast - HeROPA read-out | 3 | Oslo Børs | ||
| 14.10. | Arctic Bioscience AS: Arctic Bioscience - Announces top-line results from the phase 2b HeROPA study | 6 | Oslo Børs | ||
| 08.10. | Groupe Berkem & Arctic Bioscience Partner to Launch B-Romega: A Breakthrough in Omega-3 Innovation | 377 | Business Wire | GROUPE BERKEM ARCTIC BIOSCIENCE PARTNER TO LAUNCH B-ROMEGA: A BREAKTHROUGH IN OMEGA-3 INNOVATION The partnership introduces a breakthrough in Omega-3 supplements in North America Herring... ► Artikel lesen | |
| 25.09. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - New cellular research showing anti-psoriatic effects | 3 | Cision News | ||
| 20.09. | Arctic Bioscience AS: Arctic Bioscience - Mandatory notification of trade | 1 | Oslo Børs | ||
| 29.08. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Study de-risked by all needed patients passed 6 months, read-out expected in 4-6 weeks | 2 | Cision News | ||
| 22.08. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Invitation to presentation of half year 2024 results | 2 | Cision News | ||
| 26.07. | Arctic Bioscience AS: Arctic Bioscience - Mandatory notification of trade | - | Oslo Børs | ||
| 26.06. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - New positive data showing anti-inflammatory effects of phospholipid esters from herring roe in immune cells | 1 | Cision News |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,220 | +3,55 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
| EVOTEC | 10,070 | +1,67 % | Märkte am Morgen: Bitcoin, Talanx, Evotec, ASML, Infineon, Domino's Pizza, Palantir | Der DAX sich gestern von seiner starken Seite präsentiert und kräftig zugelegt. Am Ende ging der Leitindex 1,37 Prozent höher bei 19.263 Punkten aus dem Handel. Heute muss er mit unterschiedlichen Vorgabe... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,580 | -3,72 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| IMMUNOVANT | 26,540 | 0,00 % | Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? | ||
| KEROS THERAPEUTICS | 53,84 | -0,55 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| JANUX THERAPEUTICS | 46,500 | -5,02 % | Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,755 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| GALAPAGOS NV | 24,000 | -0,08 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| AVIDITY BIOSCIENCES | 42,530 | -2,57 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,78 | +0,03 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| BB BIOTECH | 38,650 | 0,00 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| NUVALENT | 92,65 | 0,00 % | Nuvalent-CEO Porter verkauft Aktien im Wert von 2,37 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 36,300 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| ARCTURUS THERAPEUTICS | 17,070 | +5,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ARVINAS | 25,140 | 0,00 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode |
Das Unternehmen ARCTIC BIOSCIENCE AS kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,145 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCTIC BIOSCIENCE AS finden Sie auf Wallstreet Online.
